NCT01703312View on ClinicalTrials.gov

A Study Evaluating the Efficacy of QGE031 Compared to Omalizumab in Patients With Allergic Asthma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
Allergic Asthma
Interventions
DRUG

QGE031

Drug administered by subcutaneous injection

DRUG

omalizumab

Drug administered by subcutaneous injection

DRUG

placebo

Drug administered by subcutaneous injection

Trial Locations (7)

T2N 4N1

Novartis Investigative Site, Calgary

T6G 2B7

Novartis Investigative Site, Edmonton

L8N 3Z5

Novartis Investigative Site, Hamilton

G1V 4G5

Novartis Investigative Site, Ste-Foy

S7N 0W8

Novartis Investigative Site, Saskatoon

Unknown

Novartis Investigative Site, Vancouver

S-171 76

Novartis Investigative Site, Stockholm

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY